|
Regenxbio Inc (NASDAQ: RGNX) |
|
Regenxbio Inc
RGNX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Regenxbio Inc 's sales fell
by -4.5 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2260
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.65 %
Regenxbio Inc net loss decreased from $-63 millions, to $-51 millions in IV. Quarter 2024,
• More on RGNX's Growth
|
|
Regenxbio Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 17.98 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.96.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.54.
• More on RGNX's Valuation
|
|
|
|
|
Regenxbio Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 17.98 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.96.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.54.
Regenxbio Inc Price to Book Ratio is at 1.59 lower than Industry Avg. of 1427.12. and higher than S&P 500 Avg. of 0.01
• More on RGNX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com